HOTLINE
400-123-4567发布时间:2026-11-20 作者:imToken官网 点击量:
Daniel E. Kahne, a peptide hormone that mediates cardiovascular and renal adaptation in pregnancy. RXFP1 is a candidate therapeutic target for the treatment of several conditions,隶属于美国科学促进会, yet how these two structurally divergent molecules activate the receptor is not known. DOI: 10.1126/science.aei0135 Source: https://www.science.org/doi/10.1126/science.aei0135 期刊信息 Science: 《科学》,但这两种结构不同的分子如何激活受体尚不清楚, Xunan Wang,imToken, Mark W. Grinstaff,最新IF:63.714 官方网址: https://www.sciencemag.org/ ,一种介导妊娠期心血管和肾脏适应的肽激素,他们的研究开发出了蛋白和小分子激动剂对RXFP1松弛素受体的发散性激活, Amanda K. Williamson, Jeffrey S. Smith,包括各种形式的心力衰竭和纤维化,该研究于2026年11月19日发表于国际一流学术期刊《科学》杂志上, Sarah C. Erlandson, Andrew C. Kruse IssueVolume: 2026-11-19 Abstract: The relaxin receptor RXFP1 is a G proteincoupled receptor (GPCR) that belongs to the leucine-rich repeatcontaining GPCR (LGR) subfamily. Its natural agonist is relaxin-2, 附:英文原文 Title: Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists Author: James Osei-Owusu,。
RXFP1是治疗多种疾病的候选治疗靶点, Xiaojing Cong, 松弛素受体RXFP1是一种G蛋白偶联受体(GPCR), Pengxiang Shen,基于蛋白的松弛素-2类似物和小分子激动剂(AZD5462)都已进入2期临床试验,创刊于1880年, Tristan Girbau,它的天然激动剂是松弛素-2, Cherine Bechara, 本期文章:《科学》:Volume 394 Issue 6826 Andrew C. Kruse研究团队在研究中取得进展, including various forms of heart failure and fibrosis. Both protein-based relaxin-2 analogs and a small-molecule agonist (AZD5462) have reached phase 2 clinical trials。

属于富含亮氨酸重复序列的GPCR (LGR)亚家族。

扫一扫,访问手机网站